{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:28:48Z","timestamp":1792708128111,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>90% of glioblastomas (GBM) relapse within two years of diagnosis. In contrast to the initial setting, there is no standard management for recurrent disease and options include hypofractionated stereotactic re-irradiation (re-mHSRT). The aims of this study were to investigate re-mHSRT practice in Swiss neuro-oncology centres.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A survey of 18 questions regarding re-irradiation for GBM was created and distributed electronically (SurveyMonkey, USA) to 11 radiation oncologists in Switzerland specialising in brain tumours. We evaluated the clinical outcomes of a multicentre series of patients treated with an established re-mHSRT schedule to benchmark these against the literature and investigated the radiological patterns of relapse after re-mHSRT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>8 of 11 (73%) radiation oncologists responded to the survey and re-irradiation practice was heterogeneous. The 10\u2009\u00d7\u20093.5\u00a0Gy schedule (RTOG 1205, BRIOChe trials) was used by 5\/8 respondents and 47\/50 patients with recurrent GBM treated with re-mHSRT with this schedule in daily practice were included in the analysis. The median time to re-mHSRT following completion of adjuvant RT was 23.3 (7-224) months. The median PTV at re-mHSRT was 22.0 cm<jats:sup>3<\/jats:sup> (0.9\u2013190). Combined CTV\u2009+\u2009PTV margins ranged from 0 to 10\u00a0mm and median prescription isodose was 80% (67\u2013100). 14\/47 (30%) patients received temozolomide and four (8.5%) continued bevacizumab concomitantly. On multivariable analysis, concomitant systemic therapy predicted for progression-free survival (PFS), HR 2.87 (95% CI 1-03-7.96), <jats:italic>p<\/jats:italic>\u2009=\u20090.042. Median PFS following re-mHSRT was 6.6 (0.2\u201392.5) months and 26\/47 patients (55%) received subsequent systemic therapy. The median overall survival (OS) following recurrence was 11.8 months (1.5\u201392.5), similar to the 10.8 months in the literature with the same schedule. The six-month OS rate was 37\/47 (79%), which compares well with the 73% reported in a meta-analysis of 50 publications employing various schedules. In a subgroup analysis of 36\/47 (79%) patients with MR follow-up after re-mHSRT, 8\/36 (22%) had no radiological evidence of tumour progression at a median follow-up of 9.4 months. 21\/28 (75%) radiological relapses were in-field, two were marginal and five were out of field.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Re-mHSRT with 10\u2009\u00d7\u20093.5\u00a0Gy can achieve local control in selected patients with recurrent GBM.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12883-024-03954-z","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T03:59:48Z","timestamp":1732593588000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Re-irradiation for recurrent glioblastoma: a pattern of care analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Susanne","family":"Rogers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekin","family":"Ermis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizem","family":"Cosgun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitta G.","family":"Baumert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Lomax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Ademaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Lazeroms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mayinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Mamot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Schwyzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit A.","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Riesterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"issue":"10","key":"3954_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"key":"3954_CR2","doi-asserted-by":"publisher","first-page":"109663","DOI":"10.1016\/j.radonc.2023.109663","volume":"184","author":"M Niyazi","year":"2023","unstructured":"Niyazi M, et al. ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma. Radiother Oncol. 2023;184:109663.","journal-title":"Radiother Oncol"},{"issue":"10","key":"3954_CR3","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1016\/S1470-2045(22)00447-8","volume":"23","author":"N Andratschke","year":"2022","unstructured":"Andratschke N, et al. European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making. Lancet Oncol. 2022;23(10):e469\u201378.","journal-title":"Lancet Oncol"},{"issue":"18","key":"3954_CR4","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2009.25.6941","volume":"28","author":"SE Fogh","year":"2010","unstructured":"Fogh SE, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol. 2010;28(18):3048\u201353.","journal-title":"J Clin Oncol"},{"key":"3954_CR5","doi-asserted-by":"crossref","unstructured":"Tsien CI et al. NRG Oncology\/RTOG1205: a randomized phase II trial of concurrent Bevacizumab and Reirradiation Versus Bevacizumab alone as treatment for recurrent glioblastoma. J Clin Oncol, 2022: p. JCO2200164.","DOI":"10.1200\/JCO.22.00164"},{"key":"3954_CR6","unstructured":"Murray L. BRIOChe: A trial looking at re-irradiation and chemotherapy in patients with recurrent glioblastoma. 2020."},{"issue":"1","key":"3954_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0360-3016(98)00266-1","volume":"43","author":"SW Lee","year":"1999","unstructured":"Lee SW, et al. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys. 1999;43(1):79\u201388.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"3954_CR8","doi-asserted-by":"publisher","first-page":"e0180457","DOI":"10.1371\/journal.pone.0180457","volume":"12","author":"KA Kessel","year":"2017","unstructured":"Kessel KA, et al. Modification and optimization of an established prognostic score after re-irradiation of recurrent glioma. PLoS ONE. 2017;12(7):e0180457.","journal-title":"PLoS ONE"},{"issue":"23","key":"3954_CR9","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, et al. Effect of Tumor-Treating Fields Plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a Randomized Clinical Trial. JAMA. 2017;318(23):2306\u201316.","journal-title":"JAMA"},{"issue":"9","key":"3954_CR10","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1200\/JCO.2004.06.082","volume":"22","author":"W Roa","year":"2004","unstructured":"Roa W, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22(9):1583\u20138.","journal-title":"J Clin Oncol"},{"issue":"11","key":"3954_CR11","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","volume":"376","author":"JR Perry","year":"2017","unstructured":"Perry JR, et al. Short-course Radiation plus Temozolomide in Elderly patients with Glioblastoma. N Engl J Med. 2017;376(11):1027\u201337.","journal-title":"N Engl J Med"},{"issue":"3","key":"3954_CR12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11060-013-1336-7","volume":"118","author":"TC Ryken","year":"2014","unstructured":"Ryken TC, et al. The role of cytoreductive surgery in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2014;118(3):479\u201388.","journal-title":"J Neurooncol"},{"issue":"3","key":"3954_CR13","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s10143-020-01331-1","volume":"44","author":"D Botros","year":"2021","unstructured":"Botros D, et al. Assessing the efficacy of repeat resections in recurrent glioblastoma: a systematic review. Neurosurg Rev. 2021;44(3):1259\u201371.","journal-title":"Neurosurg Rev"},{"issue":"20","key":"3954_CR14","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","volume":"377","author":"W Wick","year":"2017","unstructured":"Wick W, et al. Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med. 2017;377(20):1954\u201363.","journal-title":"N Engl J Med"},{"issue":"5","key":"3954_CR15","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","volume":"27","author":"TN Kreisl","year":"2009","unstructured":"Kreisl TN, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740\u20135.","journal-title":"J Clin Oncol"},{"issue":"28","key":"3954_CR16","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733\u201340.","journal-title":"J Clin Oncol"},{"key":"3954_CR17","first-page":"CD013579","volume":"5","author":"C McBain","year":"2021","unstructured":"McBain C, et al. Treatment options for progression or recurrence of glioblastoma: a network meta-analysis. Cochrane Database Syst Rev. 2021;5:CD013579.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"3954_CR18","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.ijrobp.2010.12.074","volume":"82","author":"KC Cuneo","year":"2012","unstructured":"Cuneo KC, et al. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2012;82(5):2018\u201324.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"3954_CR19","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s11060-018-2989-z","volume":"140","author":"JD Palmer","year":"2018","unstructured":"Palmer JD, et al. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter? J Neurooncol. 2018;140(3):623\u20138.","journal-title":"J Neurooncol"},{"issue":"9","key":"3954_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.clon.2018.05.004","volume":"30","author":"L Klobukowski","year":"2018","unstructured":"Klobukowski L, et al. A retrospective review of re-irradiating patients\u2019 recurrent high-grade gliomas. Clin Oncol (R Coll Radiol). 2018;30(9):563\u201370.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"3954_CR21","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1148\/radiol.2020200978","volume":"297","author":"P Kickingereder","year":"2020","unstructured":"Kickingereder P, et al. Noninvasive characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated recurrent glioblastoma by using dynamic susceptibility MRI: secondary analysis of the European Organization for Research and Treatment of Cancer 26101 trial. Radiology. 2020;297(1):164\u201375.","journal-title":"Radiology"},{"key":"3954_CR22","doi-asserted-by":"publisher","first-page":"102029","DOI":"10.1016\/j.ctrv.2020.102029","volume":"87","author":"M Weller","year":"2020","unstructured":"Weller M, Le Rhun E. How did lomustine become standard of care in recurrent glioblastoma? Cancer Treat Rev. 2020;87:102029.","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"3954_CR23","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699\u2013708.","journal-title":"N Engl J Med"},{"issue":"9","key":"3954_CR24","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","volume":"15","author":"W Taal","year":"2014","unstructured":"Taal W, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15(9):943\u201353.","journal-title":"Lancet Oncol"},{"issue":"3","key":"3954_CR25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/neuonc\/nop050","volume":"12","author":"AA Brandes","year":"2010","unstructured":"Brandes AA, et al. O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro Oncol. 2010;12(3):283\u20138.","journal-title":"Neuro Oncol"},{"issue":"1","key":"3954_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.radonc.2015.12.003","volume":"118","author":"M Niyazi","year":"2016","unstructured":"Niyazi M, et al. ESTRO-ACROP guideline target delineation of glioblastomas. Radiother Oncol. 2016;118(1):35\u201342.","journal-title":"Radiother Oncol"},{"issue":"2","key":"3954_CR27","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1148\/radiol.14131691","volume":"272","author":"R Jain","year":"2014","unstructured":"Jain R, et al. Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor. Radiology. 2014;272(2):484\u201393.","journal-title":"Radiology"},{"issue":"Suppl 1","key":"3954_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3171\/2016.7.GKS161460","volume":"125","author":"CM Duma","year":"2016","unstructured":"Duma CM, et al. Upfront boost Gamma Knife leading-edge radiosurgery to FLAIR MRI-defined tumor migration pathways in 174 patients with glioblastoma multiforme: a 15-year assessment of a novel therapy. J Neurosurg. 2016;125(Suppl 1):40\u20139.","journal-title":"J Neurosurg"},{"issue":"2","key":"3954_CR29","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11060-013-1290-4","volume":"116","author":"EY Kim","year":"2014","unstructured":"Kim EY, et al. Patterns of failure after radiosurgery to two different target volumes of enhancing lesions with and without FLAIR abnormalities in recurrent glioblastoma multiforme. J Neurooncol. 2014;116(2):291\u20137.","journal-title":"J Neurooncol"},{"issue":"4","key":"3954_CR30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00066-009-1753-x","volume":"185","author":"E Fokas","year":"2009","unstructured":"Fokas E, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas: a beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol. 2009;185(4):235\u201340.","journal-title":"Strahlenther Onkol"},{"issue":"3","key":"3954_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00066-018-1416-x","volume":"195","author":"L Wilke","year":"2019","unstructured":"Wilke L, et al. ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams: Statement from the DEGRO\/DGMP working group stereotactic radiotherapy and radiosurgery. Strahlenther Onkol. 2019;195(3):193\u20138.","journal-title":"Strahlenther Onkol"},{"issue":"1022","key":"3954_CR32","doi-asserted-by":"publisher","first-page":"20120414","DOI":"10.1259\/bjr.20120414","volume":"86","author":"J Sherriff","year":"2013","unstructured":"Sherriff J, et al. Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide. Br J Radiol. 2013;86(1022):20120414.","journal-title":"Br J Radiol"},{"issue":"3","key":"3954_CR33","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s11060-023-04340-4","volume":"163","author":"D Moore-Palhares","year":"2023","unstructured":"Moore-Palhares D, et al. Re-irradiation for recurrent high-grade glioma: an analysis of prognostic factors for survival and predictors of radiation necrosis. J Neurooncol. 2023;163(3):541\u201351.","journal-title":"J Neurooncol"},{"issue":"10","key":"3954_CR34","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00066-014-0676-3","volume":"190","author":"J Berberat","year":"2014","unstructured":"Berberat J, et al. Diffusion tensor imaging for target volume definition in glioblastoma multiforme. Strahlenther Onkol. 2014;190(10):939\u201343.","journal-title":"Strahlenther Onkol"},{"key":"3954_CR35","doi-asserted-by":"crossref","unstructured":"Metz MC et al. Predicting Glioblastoma recurrence from preoperative MR Scans using fractional-anisotropy maps with free-water suppression. Cancers (Basel), 2020. 12(3).","DOI":"10.3390\/cancers12030728"},{"issue":"11","key":"3954_CR36","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.3174\/ajnr.A4866","volume":"37","author":"D Daniels","year":"2016","unstructured":"Daniels D, et al. Early biomarkers from conventional and delayed-contrast MRI to predict the response to Bevacizumab in Recurrent High-Grade Gliomas. AJNR Am J Neuroradiol. 2016;37(11):2003\u20139.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"12","key":"3954_CR37","doi-asserted-by":"publisher","first-page":"e52008","DOI":"10.1371\/journal.pone.0052008","volume":"7","author":"L Zach","year":"2012","unstructured":"Zach L, et al. Delayed contrast extravasation MRI for depicting tumor and non-tumoral tissues in primary and metastatic brain tumors. PLoS ONE. 2012;7(12):e52008.","journal-title":"PLoS ONE"},{"issue":"1","key":"3954_CR38","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1148\/radiol.13131305","volume":"271","author":"BM Ellingson","year":"2014","unstructured":"Ellingson BM, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology. 2014;271(1):200\u201310.","journal-title":"Radiology"},{"issue":"1","key":"3954_CR39","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13014-020-01744-8","volume":"16","author":"M Carles","year":"2021","unstructured":"Carles M, et al. FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation? Radiat Oncol. 2021;16(1):46.","journal-title":"Radiat Oncol"},{"issue":"1","key":"3954_CR40","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13014-021-01767-9","volume":"16","author":"G Minniti","year":"2021","unstructured":"Minniti G, et al. Current status and recent advances in reirradiation of glioblastoma. Radiat Oncol. 2021;16(1):36.","journal-title":"Radiat Oncol"},{"issue":"2","key":"3954_CR41","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1148\/radiol.2532090007","volume":"253","author":"RF Barajas Jr","year":"2009","unstructured":"Barajas RF Jr., et al. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. 2009;253(2):486\u201396.","journal-title":"Radiology"},{"issue":"5","key":"3954_CR42","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00259-014-2959-4","volume":"42","author":"N Galldiks","year":"2015","unstructured":"Galldiks N, et al. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging. 2015;42(5):685\u201395.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03954-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-024-03954-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03954-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T07:28:13Z","timestamp":1751614093000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-024-03954-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3954"],"URL":"https:\/\/doi.org\/10.1186\/s12883-024-03954-z","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"1 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been updated to amend the license information.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics committee approval for the multicentre analysis was obtained from the Ethikkommission Nordwest und Zentral Schweiz (EKNZ 2023\u2009\u2212\u200900414). Patients provided informed consent for both medical therapy and consent for use of anonymised data in ethics-approved future research projects. Patients treated prior to introduction of this consent form in 2018 could not be asked.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Covered by the consent obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"462"}}